<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="ffbaf9a3-07ba-4b4f-ad79-d0ec5dcf84d7"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use MITOSOL<sup>®</sup> safely and effectively. See full prescribing information for MITOSOL<sup>®</sup>.<br/>
      <br/>MITOSOL<sup>®</sup> (mitomycin for solution) for ophthalmic use<br/>Initial U.S. Approval: 1974 </title>
   <effectiveTime value="20250423"/>
   <setId root="244002c6-c61d-43fe-9326-072797113979"/>
   <versionNumber value="10"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="805642118" root="1.3.6.1.4.1.519.1"/>
            <name>Mobius Therapeutics LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="ab992d2b-548b-4ff5-a45f-2bcc43375f33"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20221215"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="49771-002" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Mitosol</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>mitomycin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="49771-002-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C53438" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRAY"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="3"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="49771-002-03" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20120208"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Mitosol</name>
                              <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>mitomycin</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="0.2"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="50SG953SK6" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Mitomycin</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="50SG953SK6" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>Mitomycin</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>mannitol</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-USE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic classCode="OBS">
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA022572" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20120208"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Sterile Water</name>
                              <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Water</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>water</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43203" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE, GLASS"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic classCode="OBS">
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 1: Convenience Kit of Co-Package" xsi:type="CE"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA022572" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20120208"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022572" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20120208"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="56f80b15-bc58-45d7-88fa-e3f502d72cbe"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>Mitosol<sup>®</sup> is an antimetabolite indicated for use as an adjunct to ab externo glaucoma surgery. </paragraph>
               </text>
               <effectiveTime value="20171222"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Mitosol<sup>®</sup> is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. (<linkHtml href="#s1">1</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="6fd492ac-568f-47b9-83d2-996c93d9c00f"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20210423"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Mitosol<sup>®</sup> is intended for topical application to the surgical site of glaucoma filtration surgery. It is not intended for intraocular administration. (<linkHtml href="#s2">2</linkHtml>) </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Each vial of Mitosol<sup>®</sup> contains 0.2 mg of mitomycin and mannitol in a 1:2 concentration ratio. To reconstitute, add 1 mL of Sterile Water for Injection, then shake to dissolve. If product does not dissolve immediately, allow to stand at room temperature until the product has dissolved into solution. (<linkHtml href="#s3">2.2</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Fully saturate sponges provided within the Mitosol<sup>®</sup> Kit utilizing the entire reconstituted contents of the vial in the manner prescribed in the Instructions for Use. (<linkHtml href="#s4">2.3</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Apply fully saturated sponges equally to the treatment area, in a single layer, with the use of a surgical forceps. Keep the sponges on the treatment area for two (2) minutes, then remove and return to the Mitosol<sup>®</sup> Tray for defined disposal. (<linkHtml href="#s4">2.3</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_badc332a-1559-4c40-b92b-bee06ecf7cbe">
                     <id root="03ca4faf-1f6c-4ba7-bd96-21f0e2c27081"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Administration Instructions </title>
                     <text>
                        <paragraph>Mitosol<sup>®</sup> is intended for topical application to the surgical site of glaucoma filtration surgery. Mitosol<sup>®</sup> is a cytotoxic drug. It is not intended for intraocular administration. If intraocular administration occurs, cell death leading to corneal infarction, retinal infarction, and ciliary body atrophy may result. Verify pregnancy status in females of reproductive potential prior to using Mitosol<sup>®</sup>.</paragraph>
                     </text>
                     <effectiveTime value="20210423"/>
                  </section>
               </component>
               <component>
                  <section ID="s3">
                     <id root="569bca7c-8545-4a24-b4e2-d1591468c6ad"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Method of Reconstitution </title>
                     <text>
                        <paragraph>Each vial of Mitosol<sup>®</sup> contains 0.2 mg of mitomycin and mannitol in a 1:2 concentration ratio. To reconstitute, add 1 mL of Sterile Water for Injection, then shake to dissolve. If product does not dissolve immediately, allow to stand at room temperature until the product dissolves into solution. </paragraph>
                     </text>
                     <effectiveTime value="20210423"/>
                  </section>
               </component>
               <component>
                  <section ID="s4">
                     <id root="8b9f379b-b0fc-496d-9b3e-1e5574569408"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Method of Use </title>
                     <text>
                        <paragraph>Sponges provided within the Mitosol<sup>®</sup> Kit should be fully saturated with the entire reconstituted contents in the manner prescribed in the Instructions for Use. A treatment area approximating 10mm x 6mm +/- 2mm should be treated with the Mitosol<sup>®</sup>. Apply fully saturated sponges equally to the treatment area, in a single layer, with the use of a surgical forceps. Keep the sponges on the treatment area for two (2) minutes, then remove and return to the Mitosol<sup>®</sup> Tray for defined disposal in the Chemotherapy Waste Bag provided. </paragraph>
                     </text>
                     <effectiveTime value="20210423"/>
                  </section>
               </component>
               <component>
                  <section ID="s5">
                     <id root="4353acd5-4c87-43c9-a796-1774cf967090"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Stability </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Lyophilized</content> Mitosol<sup>®</sup> stored at 20°C to 25°C (68°F to 77°F) is stable for the shelf life indicated on the package. Avoid excessive heat. Protect from light. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Reconstituted</content> with 1 mL of Sterile Water for Injection at a concentration of 0.2 mg/mL, mitomycin is stable for one (1) hour at room temperature. </paragraph>
                     </text>
                     <effectiveTime value="20210423"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s6">
               <id root="490e2704-31b3-43d4-9451-5eb6cbc5bcf1"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Mitosol<sup>®</sup> is a sterile lyophilized mixture of mitomycin and mannitol, which, when reconstituted with Sterile Water for Injection, provides a solution for application in glaucoma filtration surgery. Mitosol<sup>®</sup> is supplied in vials containing 0.2 mg of mitomycin. Each vial also contains mannitol 0.4 mg, at a 1:2 ratio of mitomycin to mannitol. Each mL of reconstituted solution contains 0.2 mg mitomycin and has a pH between 5.0 and 8.0. </paragraph>
               </text>
               <effectiveTime value="20171222"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Each vial contains a sterile lyophilized mixture of 0.2 mg mitomycin and 0.4 mg mannitol; when reconstituted with Sterile Water for Injection, the solution contains 0.2 mg/mL mitomycin. (<linkHtml href="#s6">3</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s7">
               <id root="20d7fa9f-fa81-4fbc-b2c1-602110cd04f8"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <effectiveTime value="20210423"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Hypersensitivity to mitomycin. (<linkHtml href="#s8">4.1</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s8">
                     <id root="36c19095-cfe9-46b1-b0e5-62671d6729cb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.1 Hypersensitivity </title>
                     <text>
                        <paragraph>Mitosol<sup>®</sup> is contraindicated in patients that have demonstrated a hypersensitivity to mitomycin in the past. </paragraph>
                     </text>
                     <effectiveTime value="20160120"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s10">
               <id root="fda6a30b-5c06-4887-89a2-b257a4bb1dbd"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20210423"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Cell Death</content>: Mitomycin is cytotoxic. Use of mitomycin in concentrations higher than 0.2 mg/mL or use for longer than 2 minutes may lead to unintended corneal and/or scleral damage including thinning or perforation. Direct contact with the corneal endothelium will result in cell death. (<linkHtml href="#s11">5.1</linkHtml>) </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Hypotony</content>: The use of mitomycin has been associated with an increased incidence of post-operative hypotony. (<linkHtml href="#s12">5.2</linkHtml>) </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Cataract Development</content>: Use in phakic patients has been correlated to a higher incidence of lenticular change and cataract formation. (<linkHtml href="#s13">5.3</linkHtml>) </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Embryo-Fetal Toxicity</content>:  Can cause fetal harm.  Advise of potential risk to a fetus.  Verify pregnancy status in females of reproductive potential prior to use.  (<linkHtml href="#ID_3952b744-a516-4339-a6df-42ecd1cca414">5.4</linkHtml>, <linkHtml href="#s17">8.1</linkHtml>, <linkHtml href="#ID_71f7d2ee-cba8-42fc-8d62-a2e76732f7e9">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s11">
                     <id root="e48c9cca-3308-46aa-98cd-d00995200d10"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Cell Death </title>
                     <text>
                        <paragraph>Mitomycin is cytotoxic. Use of mitomycin in concentrations higher than 0.2 mg/mL or use for longer than 2 minutes may lead to unintended corneal and/or scleral damage including thinning or perforation. Direct contact with the corneal endothelium will result in cell death. </paragraph>
                     </text>
                     <effectiveTime value="20160120"/>
                  </section>
               </component>
               <component>
                  <section ID="s12">
                     <id root="ae3aff6d-64c9-45f8-aeb4-cc4633dd5792"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hypotony </title>
                     <text>
                        <paragraph>The use of mitomycin has been associated with an increased incidence of post-operative hypotony. </paragraph>
                     </text>
                     <effectiveTime value="20171222"/>
                  </section>
               </component>
               <component>
                  <section ID="s13">
                     <id root="146d24c2-7890-4f19-9672-3e0474277d0c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Cataract Formation </title>
                     <text>
                        <paragraph>Use in phakic patients has been correlated to a higher incidence of lenticular change and cataract formation. </paragraph>
                     </text>
                     <effectiveTime value="20171222"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3952b744-a516-4339-a6df-42ecd1cca414">
                     <id root="09fbc28d-78df-44ed-bc53-1f1c1c81e268"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Embryo-Fetal Toxicity </title>
                     <text>
                        <paragraph>Based on findings in animals and mechanism of action, Mitosol<sup>® </sup>can cause fetal harm when administered to a pregnant woman.  In animal reproduction studies, parenteral administration of mitomycin resulted in teratogenicity <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s17">8.1</linkHtml>, <linkHtml href="#ID_71f7d2ee-cba8-42fc-8d62-a2e76732f7e9">8.3</linkHtml>) and Clinical Pharmacology (<linkHtml href="#s23">12.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210423"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s14">
               <id root="931eb40c-4340-4329-a252-6abfe03de62a"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling: </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Cell Death <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s11">5.1</linkHtml>)] </content>
                     </item>
                     <item>
                        <caption>•</caption>Hypotony <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s12">5.2</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Cataract Formation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.3</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20210423"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most frequent adverse reactions to Mitosol<sup>®</sup> occur locally and include hypotony, hypotony maculopathy, blebitis, endophthalmitis, vascular reactions, corneal reactions, and cataract. (<linkHtml href="#_Refs15">6.1</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Mobius Therapeutics LLC at 1-877-393-6486 or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                              <br/>
                              <br/>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s15">
                     <id root="9d33a130-a025-464a-9974-71212d2eea17"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Ophthalmic Adverse Reactions </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most frequent adverse reactions to Mitosol<sup>®</sup> occur locally, as an extension of the pharmacological activity of the drug. These reactions include: </paragraph>
                        <paragraph>
                           <content styleCode="italics">Blebitis:</content> bleb ulceration, chronic bleb leak, encapsulated/cystic bleb, bleb-related infection, wound dehiscence, conjunctival necrosis, thin-walled bleb </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cornea:</content> corneal endothelial damage, epithelial defect, anterior synechiae, superficial punctuate keratitis, Descemet's detachment, induced astigmatism </paragraph>
                        <paragraph>
                           <content styleCode="italics">Endophthalmitis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hypotony:</content> choroidal reactions (choroidal detachment, choroidal effusion, serous choroidal detachment, suprachoroidal hemorrhage, hypotony maculopathy, presence of supraciliochoroidal fluid, hypoechogenic suprachoroidal effusion) </paragraph>
                        <paragraph>
                           <content styleCode="italics">Inflammation:</content> iritis, fibrin reaction </paragraph>
                        <paragraph>
                           <content styleCode="italics">Lens:</content> cataract development, cataract progression, capsule opacification, capsular constriction and/or capsulotomy rupture, posterior synechiae </paragraph>
                        <paragraph>
                           <content styleCode="italics">Retina:</content> retinal pigment epithelial tear, retinal detachment (serous and rhegatogenous) </paragraph>
                        <paragraph>
                           <content styleCode="italics">Scleritis:</content> wound dehiscence </paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular:</content> hyphema, central retinal vein occlusion, hemiretinal vein occlusion, retinal hemorrhage, vitreal hemorrhage and blood clot, subconjunctival hemorrhage, disk hemorrhage </paragraph>
                        <paragraph>
                           <content styleCode="italics">Additional Reactions:</content> macular edema, sclera thinning or ulceration, intraocular lens capture, disk swelling, malignant glaucoma, lacrimal drainage system obstruction, ciliary block, corneal vascularization, visual acuity decrease, cystic conjunctival degeneration, upper eyelid retraction, dislocated implants, severe loss of vision. </paragraph>
                     </text>
                     <effectiveTime value="20210423"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s16">
               <id root="29e94d4a-cf5c-4619-8a47-4a55b0157b66"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20210423"/>
               <component>
                  <section ID="s17">
                     <id root="28d8fafe-0807-4d37-addd-04e1f8330566"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <effectiveTime value="20210423"/>
                     <component>
                        <section ID="ID_86191047-9fc1-4355-b629-4fc1ec76ee3a">
                           <id root="78f868fc-d52a-49b1-b967-644b57505c64"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                           </title>
                           <text>
                              <paragraph>Based on findings in animals and mechanism of action <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s23">12.1</linkHtml>)]</content>, Mitosol<sup>®</sup> can cause fetal harm when administered to a pregnant woman. There are no available data on Mitosol<sup>®</sup> use in pregnant women to inform the drug-associated risk. In animal reproduction studies, parenteral administration of mitomycin resulted in teratogenicity (<content styleCode="italics">see <linkHtml href="#ID_6cd57de2-5bd1-41a7-9e39-2886598f5e52">Data</linkHtml>
                                 </content>). Advise pregnant women of the potential risk to a fetus.</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% - 4% and 15% - 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20210423"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_6cd57de2-5bd1-41a7-9e39-2886598f5e52">
                           <id root="f31bbbf6-fce5-4092-9ccb-4a27d1507581"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Data</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Animal Data</content>
                              </paragraph>
                              <paragraph>Parenteral administration of mitomycin in animal reproduction studies produced fetal malformations and embryofetal lethality.</paragraph>
                           </text>
                           <effectiveTime value="20210423"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_c4bdbb53-e98f-4559-b2b0-f69cfb425a46">
                     <id root="d9780ba2-4a81-40b2-82f1-4482ee6f25b0"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <effectiveTime value="20210423"/>
                     <component>
                        <section ID="ID_8611d42d-de4b-41de-a405-ac61622698b3">
                           <id root="9dd74b65-aaa5-4d24-a0b2-c329f659c6ef"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                           </title>
                           <text>
                              <paragraph>There are no data on the presence of mitomycin in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during and for 1 week following administration of Mitosol<sup>®</sup>.</paragraph>
                           </text>
                           <effectiveTime value="20210423"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_71f7d2ee-cba8-42fc-8d62-a2e76732f7e9">
                     <id root="a97fb9bc-252a-4bdc-b364-e6e2d594c73d"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential </title>
                     <text>
                        <paragraph>Mitosol<sup>®</sup> can cause fetal harm when administered to pregnant women <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s17">8.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210423"/>
                     <component>
                        <section ID="ID_69ddd12e-9dcd-4e96-88b1-92ba7ffa4af0">
                           <id root="35ef439f-dca2-4434-81b0-840955bd8191"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Pregnancy Testing</content>
                           </title>
                           <text>
                              <paragraph>Verify pregnancy status in females of reproductive potential prior to using Mitosol<sup>®</sup>.</paragraph>
                           </text>
                           <effectiveTime value="20210423"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s19">
                     <id root="d13df7a0-7f46-4a19-960e-4d1786b63375"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established. </paragraph>
                     </text>
                     <effectiveTime value="20160120"/>
                  </section>
               </component>
               <component>
                  <section ID="s20">
                     <id root="9e0be800-153e-474d-9ad5-f4c99a6fd186"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>No overall differences in safety and effectiveness have been observed between elderly and younger patients. </paragraph>
                     </text>
                     <effectiveTime value="20160120"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s21">
               <id root="77001ac7-2465-4c24-8873-a1322ff93599"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Mitomycin is an antibiotic isolated from the broth of <content styleCode="italics">Streptomyces verticillus Yingtanensis</content> which has been shown to have antimetabolic activity. </paragraph>
                  <paragraph>Mitomycin is a blue-violet crystalline powder with the molecular formula of C<sub>15</sub>H<sub>18</sub>N<sub>4</sub>O<sub>5</sub> and a molecular weight of 334.33. Its chemical name is 7-amino-9α-methoxymitosane and it has the following structural formula: </paragraph>
                  <renderMultiMedia ID="f01" referencedObject="mm01"/>
                  <paragraph>Mitosol<sup>®</sup> is a sterile lyophilized mixture of mitomycin and mannitol, which, when reconstituted with Sterile Water for Injection, provides a solution for application in glaucoma filtration surgery. Mitosol<sup>®</sup> is supplied in vials containing 0.2 mg of mitomycin. Each vial also contains mannitol 0.4 mg, at a 1:2 ratio of mitomycin to mannitol. Each mL of reconstituted solution contains 0.2 mg mitomycin and has a pH between 5.0 and 8.0. </paragraph>
               </text>
               <effectiveTime value="20200807"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Structural Formula
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s22">
               <id root="90eb7d62-4630-46a3-967d-fca8899d29d4"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20210423"/>
               <component>
                  <section ID="s23">
                     <id root="ecf9ee8a-f7b4-4f7d-a6f4-93b5dc14909d"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Mitosol<sup>®</sup> inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. Cellular RNA and protein synthesis may also be suppressed. </paragraph>
                     </text>
                     <effectiveTime value="20160120"/>
                  </section>
               </component>
               <component>
                  <section ID="s24">
                     <id root="12498e61-ca43-4622-9431-a4e1ef699426"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <effectiveTime value="20210423"/>
                     <component>
                        <section ID="s25">
                           <id root="77b18c72-9ca4-4a2e-8232-673d8e4fd09d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>The systemic exposure of mitomycin following ocular administration of Mitosol<sup>®</sup> in humans is unknown. Based on a comparison of the proposed dose of up to 0.2 mg to intravenous (IV) doses of mitomycin used clinically for treatment of oncologic indications (up to 20 mg/m<sup>2</sup>), systemic concentrations in humans upon ocular administration are expected to be multiple orders of magnitude lower than those achieved by IV administration. </paragraph>
                           </text>
                           <effectiveTime value="20210423"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s26">
                           <id root="e4f283b2-46b6-4496-92a6-59128b105729"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Metabolism</content>
                              </paragraph>
                              <paragraph>In humans, mitomycin is cleared from ophthalmic tissue after intraoperative topical application and irrigation, as metabolism occurs in other affected tissues. Systemic clearance is affected primarily by metabolism in the liver. The rate of clearance is inversely proportional to the maximal serum concentration because of saturation of the degradative pathways. </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Excretion</content>
                              </paragraph>
                              <paragraph>Approximately 10% of an injectable dose of mitomycin is excreted unchanged in the urine. Since metabolic pathways are saturated at relatively low doses, the percent of a dose excreted in urine increases.</paragraph>
                           </text>
                           <effectiveTime value="20210423"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s28">
               <id root="ae02ab01-57ad-4f63-8e1a-f6402d48e978"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20171222"/>
               <component>
                  <section ID="s29">
                     <id root="8d17f3e4-9172-4bbd-82d6-20557259824e"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>Adequate long-term studies in animals to evaluate carcinogenic potential have not been conducted with Mitosol<sup>®</sup>. Intravenous administration of mitomycin has been found to be carcinogenic in rats and mice. At doses approximating the recommended clinical injectable dose in humans, mitomycin produces a greater than 100 percent increase in tumor incidence in male Sprague-Dawley rats, and a greater than 50 percent increase in tumor incidence in female Swiss mice. </paragraph>
                        <paragraph>The effect of Mitosol<sup>®</sup> on fertility is unknown. </paragraph>
                     </text>
                     <effectiveTime value="20160120"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s30">
               <id root="adbcf959-ed41-43c2-9597-ba0152d48141"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <text>
                  <paragraph>In placebo-controlled studies reported in the medical literature, mitomycin reduced intraocular pressure (IOP) by 3 mmHg in patients with open-angle glaucoma when used as an adjunct to ab externo glaucoma surgery by Month 12. </paragraph>
                  <paragraph>In studies with a historical control reported in the medical literature, mitomycin reduced intraocular pressure (IOP) by 5 mmHg in patients with open-angle glaucoma when used as an adjunct to ab externo glaucoma surgery by Month 12. </paragraph>
               </text>
               <effectiveTime value="20171222"/>
            </section>
         </component>
         <component>
            <section ID="s31">
               <id root="e2472ab0-6a07-4efd-98ae-df79614f67cc"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <effectiveTime value="20210423"/>
               <component>
                  <section ID="s32">
                     <id root="09a8a31b-3533-47d1-8927-86b5bbab780f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1 How Supplied </title>
                     <text>
                        <paragraph>Mitosol<sup>®</sup> (mitomycin for solution) is available in a kit containing: </paragraph>
                        <paragraph>One             Vial containing 0.2 mg mitomycin </paragraph>
                        <paragraph>One             1 mL syringe (Sterile Water For Injection) with Safety Connector</paragraph>
                        <paragraph>One             Plunger Rod </paragraph>
                        <paragraph>One             Vial Adapter with Spike </paragraph>
                        <paragraph>One             1 mL TB Syringe, Luer Lock </paragraph>
                        <paragraph>One             Sponge Container </paragraph>
                        <paragraph>Six               3 mm Absorbent Sponges </paragraph>
                        <paragraph>Six               6 mm Absorbent Sponges </paragraph>
                        <paragraph>Six               Half Moon Sponges </paragraph>
                        <paragraph>One             Instrument Wedge Sponge </paragraph>
                        <paragraph>One             Protective Foam Pouch </paragraph>
                        <paragraph>One             Chemotherapy Waste Bag </paragraph>
                        <paragraph>One             Label, MMC (mitomycin)</paragraph>
                        <paragraph>Three kits are supplied in each carton (NDC 49771-002-03). </paragraph>
                     </text>
                     <effectiveTime value="20200807"/>
                  </section>
               </component>
               <component>
                  <section ID="s33">
                     <id root="0820acc7-bfcc-4152-8514-95b57c21abf4"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Storage and Handling </title>
                     <effectiveTime value="20210423"/>
                     <component>
                        <section ID="s34">
                           <id root="4abfe5f5-9dca-4829-8eb2-5356a91f6518"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Storage</content>
                              </paragraph>
                              <paragraph>Store kits at 20°C to 25°C (68°F to 77°F).  Avoid excessive heat. Protect from light.</paragraph>
                           </text>
                           <effectiveTime value="20210423"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s35">
                           <id root="215ed3fd-a861-4e43-a9b3-45a55040b3be"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Handling Procedures</content>
                              </paragraph>
                              <paragraph>Mitosol<sup>®</sup> is a cytotoxic drug. Procedures for Proper Handling and Disposal of anti-cancer drugs should be followed. Appropriate containment and disposal devices are included within the Mitosol<sup>®</sup> (mitomycin for solution) Kit for Ophthalmic Use. </paragraph>
                           </text>
                           <effectiveTime value="20210423"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s36">
               <id root="bdaa5634-81ed-4d08-93d7-7a79c54abbeb"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Instruct patients to discuss with their physician if they are pregnant or if they might become pregnant <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s17">8.1</linkHtml>)].</content>
                     </item>
                     <item>
                        <caption>•</caption>Instruct patients to discuss with their physician if they have demonstrated a hypersensitivity to mitomycin in the past <content styleCode="italics">[see Contraindications (<linkHtml href="#s8">4.1</linkHtml>)].</content>
                     </item>
                     <item>
                        <caption>•</caption>Nursing mothers should be advised that it is not known if Mitosol<sup>®</sup> is excreted in human milk. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during and for 1 week following administration of Mitosol<sup>®</sup>
                        <content styleCode="italics">[see Use in Specific Populations (</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID_c4bdbb53-e98f-4559-b2b0-f69cfb425a46">8.2</linkHtml>
                        </content>
                        <content styleCode="italics">)].</content>
                     </item>
                     <item>
                        <caption>•</caption>Patients should be advised of the toxicity of Mitosol<sup>®</sup> and potential complications. </item>
                  </list>
                  <paragraph>Manufactured for:<br/>Mobius Therapeutics, LLC<br/>1000 Executive Parkway<br/>Suite 224<br/>St. Louis, MO 63141 </paragraph>
               </text>
               <effectiveTime value="20210423"/>
            </section>
         </component>
         <component>
            <section ID="ID_7a6b7ca5-a30c-4dd4-9dbf-16fc57f40ba8">
               <id root="57ff6f09-6c75-453f-af61-4b9b6ac5da5d"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>  </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Mitosol</content>
                     <sup>® </sup>
                     <br/>(mitomycin for solution)<br/>0.2 mg/vial<br/>
                     <content styleCode="bold">Kit for Ophthalmic Use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Read INSTRUCTIONS FOR USE Before Proceeding</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Instructions for Use</content>
                  </paragraph>
                  <table cellpadding="7.2pt" width="100%">
                     <col width="47%"/>
                     <col width="53%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>A. <content styleCode="bold">Outer Pack</content>
                                 <br/>     (Figure A)<br/>
                                 <br/>
                              </paragraph>
                              <paragraph>     One   Sterile Chemotherapy Waste Bag</paragraph>
                              <paragraph>     One   Instructions for Use</paragraph>
                              <paragraph>     One   Package Insert</paragraph>
                              <paragraph>     One   Inner Tray</paragraph>
                              <paragraph>     Two  Patient Chart Labels</paragraph>
                              <paragraph>
                                 <br/>
                                 <br/>
                                 <content styleCode="italics">The Outer Pack is to be handled, opened, and its </content>
                                 <content styleCode="bold">STERILE </content>
                                 <content styleCode="italics">contents dispensed by the non-sterile circulating nurse.</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <renderMultiMedia ID="id41642182" referencedObject="ID_1add348d-38af-425b-8e8b-d935413a023d"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>B. <content styleCode="bold">STERILE Inner Tray<br/>
                                 </content>     (Figure B)<br/>
                                 <br/>
                              </paragraph>
                              <paragraph>     One   Vial Containing 0.2 mg mitomycin (inside protective foam pouch)</paragraph>
                              <paragraph>     One   1 mL Syringe (Sterile Water for Injection) with Safety Connector</paragraph>
                              <paragraph>     One   Plunger Rod</paragraph>
                              <paragraph>     One   Vial Adaptor with Spike (inside protective foam pouch)</paragraph>
                              <paragraph>     One   1 mL TB Syringe, Luer Lock</paragraph>
                              <paragraph>     One   Sponge Container Containing:</paragraph>
                              <paragraph>     •   Six   3 mm Absorbent Sponges</paragraph>
                              <paragraph>     •   Six   6 mm Absorbent Sponges</paragraph>
                              <paragraph>     •   Six   Half Moon Sponges</paragraph>
                              <paragraph>     •   One  Instrument Wedge Sponge</paragraph>
                              <paragraph>     One   Label, MMC (mitomycin)</paragraph>
                              <paragraph>
                                 <br/>
                                 <br/>
                                 <content styleCode="italics">The Sterile Inner Tray is to be handled, opened, and its contents assembled and dispensed by the sterile scrub technician.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">This tray and its contents are STERILE.</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <renderMultiMedia ID="id-66269582" referencedObject="ID_4995e21d-79cf-4fe6-a697-6dec4e8a56e8"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule " valign="top"/>
                           <td styleCode="Toprule Botrule " valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">1. Getting Started<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="underline">Non-Sterile Circulating Nurse:</content>
                                 </content>
                              </paragraph>
                              <paragraph>Open outer pack. Affect sterile transfer of <content styleCode="bold">ALL </content>contents to the sterile field.<br/>
                                 <br/>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="underline">Sterile Surgical Technician:</content>
                                 </content>
                              </paragraph>
                              <paragraph>Open sterile inner tray.</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <renderMultiMedia ID="id1437801377" referencedObject="ID_72f68b20-106d-43cb-9f0d-f1667278aee4"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">2. Reconstituting Mitosol<sup>®</sup>
                                    <br/>
                                 </content>
                                 <br/>
                              </paragraph>
                              <paragraph>a.  Remove vial and vial adapter from blue foam pouch.<br/>
                                 <br/>
                              </paragraph>
                              <paragraph>b.  <content styleCode="bold">
                                    <content styleCode="underline">Screw</content>
                                 </content> white plunger rod to rubber plunger of pre‑filled syringe. <content styleCode="bold">(Fig. 1)<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                              <paragraph>c.  <content styleCode="bold">
                                    <content styleCode="underline">Press firmly</content>
                                 </content> and screw the <content styleCode="bold">
                                    <content styleCode="underline">blue end</content>
                                 </content> of the vial adapter into the <content styleCode="bold">
                                    <content styleCode="underline">blue end</content>
                                 </content> of the syringe connector. <content styleCode="bold">(Fig. 2)</content>
                                 <br/>
                                 <br/>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">NOTE: Do not force plunger. Syringe will not operate if vial adapter and syringe connector are not properly connected. Forcing plunger may result in syringe leakage and Mitosol<sup>®</sup> exposure.</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                              <renderMultiMedia ID="id-279266892" referencedObject="D34A5041-4E3D-45C9-86CA-CB7DCF9D0F7F"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>d.  Stand vial upright on a sturdy, flat surface and push on the vial lid until seated and secure. <content styleCode="bold">(Fig. 3)</content>
                                 <br/>
                                 <br/>
                              </paragraph>
                              <paragraph>e.  Inject entire contents of sterile water (1 ml) into vial. <content styleCode="bold">(Fig. 4) </content>Do not force syringe plunger. See note at step 2.<br/>
                                 <br/>
                              </paragraph>
                              <paragraph>f.  <content styleCode="bold">
                                    <content styleCode="underline">IMPORTANT</content>: </content>INVERT VIAL REPEATEDLY to saturate <content styleCode="bold">ALL </content>drug product, including that adhering to stopper, then shake until complete reconstitution of Mitosol<sup>®</sup>. If product does not dissolve immediately, allow to stand at room temperature until the product has dissolved into solution.</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id-1633088545" referencedObject="EAF27631-CAAC-43FA-BA2E-9F5DA4A72020"/>
                              <renderMultiMedia ID="id-392825239" referencedObject="D2943AE4-F9D7-4F6F-9623-2577B124AAF9"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">3. Preparing sponges<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                              <paragraph>a.  <content styleCode="bold">
                                    <content styleCode="italics">Invert vial and syringe</content>
                                 </content> and draw full volume of medication into syringe. <content styleCode="bold">(Fig. 5)<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                              <paragraph>b.  Remove all sponges from sponge tray.<br/>
                                 <br/>
                              </paragraph>
                              <paragraph>c.  Return to sponge tray only those sponges to be saturated with Mitosol<sup>®</sup>.<br/>
                                 <br/>
                              </paragraph>
                              <paragraph>d. Unscrew the syringe with safety connector from vial and vial adapter. <content styleCode="bold">(Fig. 6)</content> Note: <content styleCode="bold">DO NOT</content> remove safety connector from syringe.<content styleCode="bold">
                                    <br/>
                                    <br/>
                                 </content>
                              </paragraph>
                              <paragraph>e.  Place vial and vial adaptor in chemotherapy waste disposal bag (yellow bag), and set bag aside, within sterile field, for additional use.<br/>
                                 <br/>
                              </paragraph>
                              <paragraph>f.  Take sponge container from sterile inner tray.<br/>
                                 <br/>
                              </paragraph>
                              <paragraph>g.  Screw both syringes into sponge container; the TB syringe to one end, the syringe with reconstituted Mitosol<sup>®</sup> to the other.</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                              <renderMultiMedia ID="id-342558533" referencedObject="E2064CA8-ADC4-44FA-86B0-41C1BAA84D34"/>
                              <renderMultiMedia ID="id1978640171" referencedObject="ID_3914815d-5f05-41ac-afb2-ab091e9001ad"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>h.  <content styleCode="bold">
                                    <content styleCode="italics">Mitosol<sup>®</sup> must be used within 1 hour of reconstitution:<br/>
                                       <br/>
                                    </content>
                                 </content>
                              </paragraph>
                              <paragraph>•  Inject medication into sponge container, saturating sponges. Reconstituted Mitosol<sup>®</sup> should remain undisturbed in sponge container for <content styleCode="bold">
                                    <content styleCode="underline">60 seconds</content>
                                 </content>. <content styleCode="bold">(Fig. 7)</content> Do not force syringe plunger. See note at step 2.<br/>
                                 <br/>
                              </paragraph>
                              <paragraph>•  If any excess fluid remains, withdraw plunger of TB syringe, drawing excess fluid/air into syringe.</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id126750795" referencedObject="ID_2d33a170-1f6a-4699-9c23-24ae5163b233"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">4. Using Mitosol<sup>®</sup>
                                    <br/>
                                    <br/>
                                 </content>
                              </paragraph>
                              <paragraph>a.  With both syringes connected, the TB syringe to one end, the pre-filled syringe to the other, open sponge container, offering contents to surgeon for placement on surgical site. <content styleCode="bold">(Fig. 8)<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                              <paragraph>b.  Apply saturated sponges to surgical site for two minutes. Remove sponges from eye and copiously irrigate surgical site.<br/>
                                 <br/>
                              </paragraph>
                              <paragraph>c.  As used sponges are removed from surgical site, accept used sponges back into sponge container for disposal. Close container lid.<br/>
                                 <br/>
                              </paragraph>
                              <paragraph>d.  With syringes still connected to sponge container, remove entire assembly from surgical field in chemotherapy waste disposal bag.</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <renderMultiMedia ID="id1731190523" referencedObject="ID_19912e11-f7d1-4d2d-9774-3a748a452c5b"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">DISPOSE OF CHEMOTHERAPY WASTE BAG AND ITS CONTENTS AS CHEMOTHERAPY WASTE</content>
                     </content>
                  </paragraph>
                  <paragraph>US Patents #7,806,265, #8,186,511, #D685,962, #D685,963, #9,205,075, #9,539,241 and #9,649,428; other international patents issued and pending.</paragraph>
                  <paragraph>
                     <content styleCode="bold">A4807998-2 <br/>Rev. 07/20</content>
                  </paragraph>
               </text>
               <effectiveTime value="20200807"/>
               <component>
                  <observationMedia ID="ID_1add348d-38af-425b-8e8b-d935413a023d">
                     <text>Figure A: Outer Pack</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_4995e21d-79cf-4fe6-a697-6dec4e8a56e8">
                     <text>Figure B: Sterile Inner Tray</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_72f68b20-106d-43cb-9f0d-f1667278aee4">
                     <text>Figure 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="D34A5041-4E3D-45C9-86CA-CB7DCF9D0F7F">
                     <text>Figure 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="EAF27631-CAAC-43FA-BA2E-9F5DA4A72020">
                     <text>Figure 3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="D2943AE4-F9D7-4F6F-9623-2577B124AAF9">
                     <text>Figure 4</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="E2064CA8-ADC4-44FA-86B0-41C1BAA84D34">
                     <text>Figure 5</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_3914815d-5f05-41ac-afb2-ab091e9001ad">
                     <text>Figure 6</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_2d33a170-1f6a-4699-9c23-24ae5163b233">
                     <text>Figure 7</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_19912e11-f7d1-4d2d-9774-3a748a452c5b">
                     <text>Figure 8</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a907337b-ab7c-4148-bbd0-22a557d104f2">
               <id root="387822b9-4afc-4126-83a0-9b3a4027996d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - VIAL LABEL </title>
               <text>
                  <renderMultiMedia ID="id370738949" referencedObject="B2BFE4FE-B725-4489-B549-5B0CF3253FD9">
                     <caption>Vial Label</caption>
                  </renderMultiMedia>
                  <paragraph>NDC 49771-002-02</paragraph>
                  <paragraph>
                     <content styleCode="bold">Mitosol<sup>®</sup>
                        <br/>
                     </content>(mitomycin for solution)</paragraph>
                  <paragraph>
                     <content styleCode="bold">0.2 mg/vial</content>
                  </paragraph>
                  <paragraph>Lyophilized Mitomycin for<br/>reconstitution<br/>For ophthalmic use<br/>Protect from light.<br/>Single Use Vial<br/>Dose: See Package Insert.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>Store at 20°-25°C (68°-77°F).</paragraph>
                  <paragraph>Manufactured for: <br/>Mobius Therapeutics, LLC<br/>1000 Executive Parkway<br/>Suite 224<br/>St. Louis, MO 63141</paragraph>
                  <paragraph>Manufactured by:<br/>Intas Pharmaceuticals Ltd.<br/>Ahmedabad-382 210, INDIA.</paragraph>
                  <paragraph>Mfg. Lic. No.: G/28/1026</paragraph>
                  <paragraph>10 9480 0 6029283 INL5021</paragraph>
               </text>
               <effectiveTime value="20241125"/>
               <component>
                  <observationMedia ID="B2BFE4FE-B725-4489-B549-5B0CF3253FD9">
                     <text>Principal Display Panel - Vial Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_1de50bf8-30ec-4b94-9556-7b69c6f909dd">
               <id root="1bc57b29-4eb8-458e-98b0-48e3bef6713b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - VIAL LABEL-New </title>
               <text>
                  <renderMultiMedia ID="id2067677871" referencedObject="ID_0f8dcf5c-a529-4297-8f59-9d3704369f62">
                     <caption>Vial Label</caption>
                  </renderMultiMedia>
                  <paragraph>NDC 49771-002-02</paragraph>
                  <paragraph>
                     <content styleCode="bold">Mitosol<sup>®</sup>
                        <br/>
                     </content>(mitomycin for solution)</paragraph>
                  <paragraph>
                     <content styleCode="bold">0.2 mg/vial</content>
                  </paragraph>
                  <paragraph>Lyophilized Mitomycin for<br/>reconstitution<br/>For ophthalmic use<br/>Protect from light.<br/>Single Use Vial<br/>Dose: See Package Insert.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>Store at 20°-25°C (68°-77°F).</paragraph>
                  <paragraph>Manufactured for: <br/>Mobius Therapeutics, LLC<br/>1000 Executive Parkway<br/>Suite 224<br/>St. Louis, MO 63141</paragraph>
                  <paragraph>Lot:<br/>EXP Date<br/>YYYY-MM-DD</paragraph>
               </text>
               <effectiveTime value="20250423"/>
               <component>
                  <observationMedia ID="ID_0f8dcf5c-a529-4297-8f59-9d3704369f62">
                     <text>Principal Display Panel - Vial Label-New</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8bbb29e4-3ac8-407c-b1af-ae5b0f5f0ffd">
               <id root="e8fc6600-8ee7-49b4-9cda-70f23eb1a4e3"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - OUTER KIT PACKAGE </title>
               <text>
                  <renderMultiMedia ID="id-743189882" referencedObject="ID_340f45e0-1603-4021-964a-9ca1586b2fbb">
                     <caption>Outer Kit Package</caption>
                  </renderMultiMedia>
                  <paragraph>
                     <content styleCode="bold">Mitosol<sup>®</sup>
                        <br/>
                     </content>(mitomycin for solution)<br/>0.2 mg/vial</paragraph>
                  <paragraph>
                     <content styleCode="bold">Kit for Ophthalmic Use</content>
                  </paragraph>
                  <paragraph>Manufactured for:<br/>Mobius Therapeutics, LLC<br/>1000 Executive Parkway<br/>Suite 224<br/>St. Louis, MO 63141 USA<br/>+1 314-615-6930<br/>1-877-EYE-MITO (1-877-393-6486)</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx ONLY</content>
                  </paragraph>
                  <paragraph>US Patents #7,806,265, #8,186,511, #D685,962,<br/>#D685,963, #9,205,075, #9,539,241 and #9,649,428;<br/>other international patents issued and pending.</paragraph>
                  <paragraph>©2019 Mobius Therapeutics, LLC</paragraph>
                  <paragraph>
                     <content styleCode="bold">mobius<br/>
                     </content>therapeutics™</paragraph>
                  <paragraph>A1426418-1 <br/>Rev. 8/19</paragraph>
                  <paragraph>NDC #49771-002-01<br/>Re-Order #MOB.2</paragraph>
                  <paragraph>Each Mitosol<sup>®</sup> Kit Contains:<br/>   One   Chemotherapy Waste Bag<br/>   One   Instructions for Use<br/>   One   Package Insert<br/>   One   Inner Tray<br/>   Two  Patient Chart Labels</paragraph>
                  <paragraph>Inner Tray Contains:<br/>   One   Vial Containing 0.2 mg mitomycin<br/>             (inside protective foam pouch)<br/>   One   1 mL Syringe (Sterile Water for Injection) <br/>             with Safety Connector<br/>   One   Plunger Rod<br/>   One   Vial Adaptor with Spike (inside protective foam pouch)<br/>   One   1 mL TB Syringe, Luer Lock<br/>   One   Sponge Container Containing:<br/>      Six    3 mm Absorbent Sponges<br/>      Six    6 mm Absorbent Sponges<br/>      Six    Half Moon Sponges<br/>      One   Instrument Wedge Sponge<br/>   One   Label, MMC</paragraph>
                  <paragraph>
                     <content styleCode="bold">Contents STERILE in unopened undamaged package.</content>
                  </paragraph>
                  <paragraph>Storage: Store kits at 20° - 25° C (68° - 77° F). Protect from light.</paragraph>
                  <paragraph>
                     <content styleCode="bold">HD CAUTION: HAZARDOUS DRUG<br/>
                     </content>OBSERVE SPECIAL HANDLING, ADMINISTRATION<br/>AND DISPOSAL REQUIREMENTS</paragraph>
               </text>
               <effectiveTime value="20250423"/>
               <component>
                  <observationMedia ID="ID_340f45e0-1603-4021-964a-9ca1586b2fbb">
                     <text>Principal Display Panel - Outer Kit Package</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>